ATE477274T1 - Gegen clostridium difficile gerichtete antikörper - Google Patents
Gegen clostridium difficile gerichtete antikörperInfo
- Publication number
- ATE477274T1 ATE477274T1 AT04727315T AT04727315T ATE477274T1 AT E477274 T1 ATE477274 T1 AT E477274T1 AT 04727315 T AT04727315 T AT 04727315T AT 04727315 T AT04727315 T AT 04727315T AT E477274 T1 ATE477274 T1 AT E477274T1
- Authority
- AT
- Austria
- Prior art keywords
- clostridium difficile
- directed against
- antibodies directed
- against clostridium
- seq
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0309126.1A GB0309126D0 (en) | 2003-04-17 | 2003-04-17 | Clostridium difficile focussed antibodies |
| PCT/GB2004/001619 WO2004094474A1 (en) | 2003-04-17 | 2004-04-14 | Clostridium difficile focussed antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE477274T1 true ATE477274T1 (de) | 2010-08-15 |
Family
ID=9957095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04727315T ATE477274T1 (de) | 2003-04-17 | 2004-04-14 | Gegen clostridium difficile gerichtete antikörper |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070071763A1 (de) |
| EP (2) | EP1613655B1 (de) |
| JP (1) | JP2007527370A (de) |
| AT (1) | ATE477274T1 (de) |
| CA (1) | CA2522086A1 (de) |
| DE (1) | DE602004028592D1 (de) |
| GB (1) | GB0309126D0 (de) |
| WO (1) | WO2004094474A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130267D0 (en) * | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
| GB0414886D0 (en) * | 2004-07-02 | 2004-08-04 | Neutec Pharma Plc | Treatment of bacterial infections |
| WO2006071877A2 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| EP2088432A1 (de) * | 2008-02-11 | 2009-08-12 | MorphoSys AG | Verfahren zur Identifikation eines Antikörpers oder eines Targets |
| EP2405940B1 (de) | 2009-02-20 | 2021-08-04 | Secretary of State for Health and Social Care | Antikörper gegen clostridium difficile toxine |
| SG175407A1 (en) | 2009-05-29 | 2011-11-28 | Morphosys Ag | A collection and methods for its use |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| NZ609707A (en) | 2010-11-19 | 2014-12-24 | Morphosys Ag | A collection and methods for its use |
| BR112014004162A2 (pt) | 2011-08-22 | 2018-04-24 | Cangene Corp | anticorpos contra clostridium difficile |
| CA2856085C (en) | 2011-11-18 | 2020-06-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
| NZ714516A (en) | 2012-03-02 | 2017-06-30 | Regeneron Pharma | Human antibodies to clostridium difficile toxins |
| JPWO2014061783A1 (ja) * | 2012-10-19 | 2016-09-05 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| US10117933B2 (en) * | 2012-11-28 | 2018-11-06 | Emergent Biosolutions Canada Inc. | Antibodies against Clostridium difficile |
| SG11201503719WA (en) * | 2012-11-29 | 2015-06-29 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC) |
| SG11202005557TA (en) * | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| US20230348586A1 (en) * | 2020-09-21 | 2023-11-02 | The Board Of Regents Of The University Of Texas System | Therapeutic agents and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| DE3430339C1 (de) | 1984-08-17 | 1986-02-20 | Nixdorf Computer Ag, 4790 Paderborn | Empfangsschaltung fuer ein bipolares Eingangssignal |
| EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| ATE120492T1 (de) | 1987-09-09 | 1995-04-15 | Celltech Ltd | Fv antikörperfragment-herstellung. |
| US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| NZ291659A (en) | 1994-09-06 | 2001-04-27 | Galagen Inc | Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile |
| GB9621295D0 (en) * | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| US6214341B1 (en) | 1997-10-20 | 2001-04-10 | Oravax | Passive immunization against Clostridium difficile disease |
| WO1999050399A2 (en) * | 1998-04-01 | 1999-10-07 | Danisco A/S | Non-maltogenic exoamylases and their use in retarding retrogradation of starch |
| US6951646B1 (en) * | 1998-07-21 | 2005-10-04 | Genmab A/S | Anti hepatitis C virus antibody and uses thereof |
| PT1107996E (pt) * | 1998-08-28 | 2002-10-31 | Genentech Inc | Anticorpos humanos anti-factor ix/ixa |
| GB0008305D0 (en) | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
| US20030054009A1 (en) | 2001-02-09 | 2003-03-20 | Windle Henry J. | Clostridium difficile vaccine |
| GB0130267D0 (en) * | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
-
2003
- 2003-04-17 GB GBGB0309126.1A patent/GB0309126D0/en not_active Ceased
-
2004
- 2004-04-14 EP EP04727315A patent/EP1613655B1/de not_active Expired - Lifetime
- 2004-04-14 WO PCT/GB2004/001619 patent/WO2004094474A1/en not_active Ceased
- 2004-04-14 US US10/553,152 patent/US20070071763A1/en not_active Abandoned
- 2004-04-14 CA CA002522086A patent/CA2522086A1/en not_active Abandoned
- 2004-04-14 EP EP10008332A patent/EP2261253A3/de not_active Withdrawn
- 2004-04-14 DE DE602004028592T patent/DE602004028592D1/de not_active Expired - Lifetime
- 2004-04-14 AT AT04727315T patent/ATE477274T1/de not_active IP Right Cessation
- 2004-04-14 JP JP2006506126A patent/JP2007527370A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB0309126D0 (en) | 2003-05-28 |
| EP1613655A1 (de) | 2006-01-11 |
| EP2261253A3 (de) | 2011-06-01 |
| US20070071763A1 (en) | 2007-03-29 |
| WO2004094474A1 (en) | 2004-11-04 |
| DE602004028592D1 (de) | 2010-09-23 |
| JP2007527370A (ja) | 2007-09-27 |
| CA2522086A1 (en) | 2004-11-04 |
| EP1613655B1 (de) | 2010-08-11 |
| EP2261253A2 (de) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE477274T1 (de) | Gegen clostridium difficile gerichtete antikörper | |
| NZ588457A (en) | Humanized anti-factor d antibodies and uses thereof | |
| DE60322188D1 (de) | Zytokin (zcytor17-ligand) | |
| IL267186B (en) | Regulatory t-cell epitopes, their preparations and uses | |
| DE60131456D1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
| WO2003100033A3 (en) | ANTI-αvβ6 ANTIBODIES | |
| NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
| ATE554107T1 (de) | Als therapeutika geeignete monovalente antikörperfragmente | |
| NZ584838A (en) | Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof | |
| EE200700052A (et) | Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ626665A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| NZ590890A (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| NZ597023A (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
| NZ585622A (en) | Hepatitis c virus antibodies | |
| NZ717847A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
| ATE446972T1 (de) | Il-1 bindende antikörper und fragmente davon | |
| NZ598063A (en) | Gram-positive bacteria specific binding compounds | |
| EA200300464A1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ | |
| WO2007117577A3 (en) | High affinity human antibodies to human il-18 receptor | |
| NZ547629A (en) | Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb | |
| EE200500012A (et) | Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks | |
| ATE449177T1 (de) | Staphylococcus epidermidis antigene | |
| EP2098594A4 (de) | Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper | |
| ATE414154T1 (de) | Moraxella (branhamella) catarrhalis antigene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |